Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, Jonathan; El‐Haddad, Ghassan; M. Wolin, Edward; Hendifar, Andrew; C. Yao, James; Chasen, Beth; Mittra, Erik; L. Kunz, Pamela; H. Kulke, Matthew; A. Jacene, Heather; Bushnell, David; M. O’Dorisio, Thomas; P. Baum, Richard; Kulkarni, Harshad; Caplin, Martyn; Lebtahi, Rachida; J. Hobday, Timothy; S. Delpassand, Ebrahim; Van Cutsem, Eric; B. Benson, Al; Srirajaskanthan, Rajaventhan; Pavel, Marianne; Font de Mora, Jaime; Berlin, Jordan; Grande, Enrique; S. Reed, Nicholas; Seregni, Ettore; Öberg, Kjell; Lopera Sierra, Maribel; Santoro, Paola; Thevenet, Thomas; L. Erion, Jack; Ruszniewski, Philippe; J. Kwekkeboom, Dik; P. Krenning, Eric

doi:10.1056/nejmoa1607427

Public

Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors

Published in New England Journal of Medicine • Jan 11, 2017

Authors:

Jonathan Strosberg

Ghassan El‐Haddad

Edward M. Wolin

Abstract

BACKGROUND: Lu)-Dotatate in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumors. METHODS: Lu-Dotatate group) or octreotide LAR alone (113 patients) administered intramuscularly at a dose of 60 mg every 4 weeks (control group). The primary end point was pr...

Subject

Midgut

Neuroendocrine tumors

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!